A roundtable discussion, moderated by Laurence Albiges, MD, PhD, discussed the risk stratification and management of metastatic nccRCC, along with recent advancements in targeted therapies and immuno-agents, treatment sequencing and combination approaches, and adjuvant therapy options. Dr. Albiges was joined by Renée Maria Saliby, MD, MSc; Tian Zhang, MD; and Shahla Bari, MD.
In the first segment of the roundtable series, the panel explores the evolution of our understanding of nccRCC, discussing its classification, molecular distinctions, and prognostic criteria.
